Summary
The effects of prenylamine, verapamil, propranolol, INPEA, and pindolol on the uptake of serotonin by human platelets were investigatedin vitro andin vivo. Serotonin uptakein vitro was diminished by these drugs. Their order of potency, according to IC 50 values estimated from the dose response curves was: propranolol > prenylamine > verapamil > INPEA > pindolol. The inhibitory activity of these drugsin vivo was also studied by measuring serotonin uptake by platelets isolated 90 min after oral administration to healthy volunteers of 10 µmoles of propranolol, INPEA and prenylamine, all approximately 3 mg/kg; verapamil, approximately 5 mg/kg; and 2 µmoles/kg (0.5 mg/kg) of pindolol. In agreement with the degree of inhibition observedin vitro, propranolol was more effective than verapamil and INPEA, and, as predicted from thein vitro experiments, pindolol showed no measurable membrane activity. Prenylamine, an effective inhibitor of serotonin uptake by human plateletsin vitro, was activein vivo only after repeated oral doses of 10 µmoles/kg. It is concluded that measurement of the uptake of serotonin by human platelets is a sensitive method for investigating non-specific effects of drugs on membrane functionsin vivo as well asin vitro.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bogdanski, D.F., Pletscher, A., Brodie, B.B., Udenfriend, S.: Identification and assay of serotonin in brain. J. Pharmacol. exp. Ther.117, 82–88 (1956).
Boullin, D.J., O'Brien, R.A.: Accumulation of quinidine by human blood platelets: effects on platelet ultrastructure and 5-hydroxytryptamine. Brit. J. Pharmacol.42, 114–126 (1971).
Carlsson, A., Waldeck, B.: Inhibition of3H-metaraminol uptake by antidepressive and related agents. J. Pharmacol.17, 243–244 (1965).
Dengler, H.J., Eichelbaum, M.: Untersuchungen zum Verhalten von14C-D,L-Prenylamin im Organismus. Naunyn-Schmiedebergs Arch. Pharmak.260, 105–106 (1968).
Dollery, C.T., Paterson, J.W., Conolly, M.E.: Clinical pharmacology of beta-receptor-blocking drugs. Clin. Pharmacol. Therap.10, 765–799 (1969).
Eichelbaum, M., Schomerus, M., Dengler, H.J.: Zur Pharmakokinetik von Prenylamin (Segontin®) beim Menschen. Verhdl. Dtsch. Ges. inn. Med.76, 942 (1970).
Fitzgerald, J.D.: Perspectives in adrenergic beta-receptor blockade. Clin. Pharmacol. Therap.10, 292–306 (1969).
Grobecker, H., Lemmer, B.: Influence of coronary dilators on the uptake of serotonin by human platelets and adrenaline by chromaffine granules. Experientia27, 299–301 (1971).
Grobecker, H., Schmid, B., Fengler, H.J., Palm, D., Quiring, K., May, B., Helmstaedt, D., Moon, H.K.: Influence of prenylamine on the cardiovascular effects of tyramine, noradrenaline and adrenaline in man. Europ. J. clin. Pharmacol.3, 137–143 (1971a).
Grobecker, H., Lemmer, B., Hellenbrecht, D., Wiethold, G.: The influence of prenylamine, verapamil, propranolol, D,L-INPEA, and LB 46 on serotonin uptake by human platelets in vitro and in vivo. Naunyn-Schmiedebergs. Arch. Pharmak. Suppl. to Vol.270, R 46 (1971b).
Grobecker, H., Hellenbrecht, D., Lemmer, B., Palm, D., Schmid, B.: Über die Wirkung von Oxyfedrin auf Freisetzung und Aufnahme von Noradrenalin und Serotonin. In Action of Oxyfedrine, 119–125. Stuttgart, New York: F.K. Schattauer Verlag 1972.
Hellenbrecht, D., Wiethold, G., Grobecker, H.: Influence ofβ-adrenergic blocking agents on the excitability of frog nerve and myocardium. Naunyn-Schmiedebergs Arch. Pharmacol. Suppl. to Vol.274, R 50 (1972).
Hughes, F.B., Brodie, B.B.: The mechanism of serotonin and catecholamine uptake by platelets. J. Pharmacol. exp. Ther.127, 96–102 (1959).
Lemmer, B., Wiethold, G., Hellenbrecht, D., Bak, I.J., Grobecker, H.: Human blood platelets as cellular models for investigation of membrane active drugs. Int. Symp. on metabolism and membrane permeability of erythrocytes, thrombocytes and leucocytes, Vienna, June (in press), (1972a).
Lemmer, B., Wiethold, G., Hellenbrecht, D., Bak, I.J., Grobecker, H.: Human blood platelets as cellular models for investigation of membrane active drugs: beta-adrenergic blocking agents. Naunyn-Schmiedeberg's Arch. Pharmacol.275, 299–313 (1972b).
Levy, J.V.: Myocardial and local anesthetic actions of β-adrenergic receptor blocking drugs: relationship to physicochemical properties. Europ. J. Pharmacol.2, 250–257 (1968).
Mason, D.T., Spann, J.F., Zelis, R., Amsterdam, E.A.: The clinical pharmacology and therapeutic applications of the antiarrhythmic drugs. Clin. Pharmacol. Ther.11, 460–480 (1970).
May, B., Helmstaedt, D., Lemmer, B., Palm, D.: The influence of prenylamine on the amine content of blood platelets. Naunyn-Schmiedebergs Arch. Pharmak. Suppl. to Vol.270, R 95 (1971).
Pacha, W.L.: A method for the fluorimetric determination of 4-(2-hydroxy-3-isopropyl-aminopropoxy) indole (LB 46), a β-blocking agent, in plasma and urine. Experientia25, 802–803 (1969).
Palm, D., Grobecker, H.: On the metabolism of prenylamine (Segontin®). Experientia24, 467–469 (1968).
Palm, D., Fengler, H.J., Grobecker, H.: Urinary excretion of amphetamine in man after administration of prenylamine. Life Sciences I8, 247–257 (1969).
Palm, D., Grobecker, H., Bak, I.J.: Membrane effects of catecholamine releasing drugs. In: New Aspects of Storage and Release Mechanisms of Catecholamines, pp. 188–198. Berlin, Heidelberg, New York: Springer 1970.
Pletscher, A.: Metabolism, transfer and storage of 5-hydroxytryptamine in blood platelets. Br. J. Pharmacol. Chemother.32, 1–16 (1968).
Schmidt, F.H.: Enzymatische Methoden zur Bestimmung von Blut- und Harnzucker unter Berücksichtigung von Vergleichsuntersuchungen mit klassischen Methoden. Internist4, 554–559 (1963).
Seeman, P.M.: Membrane stabilization by drugs: tranquillizers, steroids, and anesthetics. Int. Rev. Neurobiol.9, 145–221 (1966).
Shand, D.G., Nuckolls, E.M., Oates, J.A.: Plasma propanolol levels in adults with observations in four children. Clin. Pharmacol. Ther.11, 112–120 (1970).
Somani, P., Lum, K.B.: Blockade of epinephrine- and ouabain-induced cardiac arrhythmias in the dog heart-lung preparation. J. Pharmacol. exp. Ther.152, 235–242 (1966).
Szekeres, L., Papp, G.J.: Antiarrhythmic compounds. Progress in drug research12, 292–369 (1968).
Szekeres, L., Papp, G.J.: Experimental cardiac arrhythmias and antiarrhythmic drugs. Budapest: Akadémiae Kiadó 1971.
Wagner, J.: Beitrag zur Pharmakologie der β-Adrenolytika. Dtsch. med. Wschr.95, 2442–2448 (1970).
Walle, Th., Gaffney, T.E.: Propranolol metabolism in man and dog: mass spectrometric identification of six new metabolites. J. Pharmacol. exp. Ther.182, 83–92 (1972).
Wiethold, G., Lemmer, B., Hellenbrecht, D., Grobecker, H., Palm, D.: Conformational changes in membranes by β-sympatholytic agents. Naunyn-Schmiedebergs Arch. Pharmacol. Suppl. to Vol.274, R 125 (1972).
Author information
Authors and Affiliations
Additional information
Supported by a grant from the Deutsche Forschungsgemeinschaft.
A preliminary report of this work has been presented at the 12. Frühjahrstagung der Deutschen Pharmakologischen Gesellschaft, Mainz 1971 (Grobeckeret al., 1971).
Rights and permissions
About this article
Cite this article
Grobecker, H., Lemmer, B., Hellenbrecht, D. et al. Inhibition by antiarrhythmic and β-sympatholytic drugs of serotonin uptake by human platelets: Experimentsin vitro andin vivo . Eur J Clin Pharmacol 5, 145–150 (1973). https://doi.org/10.1007/BF00564894
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00564894